Tirzepatide works by activating both the GLP-1 and GIP receptors in your brain and pancreas, creating a dual mechanism that addresses hunger signals and metabolic function
When moving from tirzepatide to semaglutide, there is no validated dose equivalence between the two agents due to their differing receptor profiles
The GIP receptor activation adds metabolic effects that pure GLP-1 agonists do not provide, including potential benefits for bone formation and gut motility that may actually buffer against certain gastrointestinal side effects
Initial consultation, labs, prescription
These new vials not only help us meet the high demand for our obesity medicine, but also broaden access for patients seeking a safe and effective treatment option, Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA, said in a statement